| Trial Identifier: | D1690L00067 |
| Sponsor: | AstraZeneca |
| NCTID:: | NCT02564926 |
| Start Date: | January 2016 |
| Primary Completion Date: | January 2018 |
| Study Completion Date: | January 2018 |
| Condition: | Diabetes: Type 2 |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Translation | |
| Korean Translation |
| Country | Location |
|---|---|
| South Korea | Ansan-si, South Korea, 15355 |
| South Korea | Bucheon-si, South Korea, 14647 |
| South Korea | Changwon-si, South Korea, 51353 |
| South Korea | Daegu, South Korea, 41931 |
| South Korea | Daejeon-si, South Korea, 35233 |
| South Korea | Goyang-si, South Korea, 10326 |
| South Korea | Guri-si, South Korea, 11923 |
| South Korea | Incheon, South Korea, 21565 |
| South Korea | Seongnam-si, South Korea, 13620 |
| South Korea | Seoul, South Korea, 06273 |
| South Korea | Seoul, South Korea, 143729 |
| South Korea | Seoul, South Korea, 01830 |
| South Korea | Seoul, South Korea, 05278 |
| South Korea | Seoul, South Korea, 04401 |
| South Korea | Seoul, South Korea, 04619 |
| South Korea | Suwon-si, South Korea, 16499 |
| South Korea | Suwon-si, South Korea, 16247 |
| South Korea | Uijeongbu-si, South Korea, 11765 |
| South Korea | Wonju-si, South Korea, 220-701 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company